Therapeutic Index

    Each Vial 5ml contains:

    Composition:

    Abciximab .....................................................................2 mg

    Indications :

    Platelet aggregation inhibition as adjunct to percutaneous   

    transluminal coronary angioplasty or atherectomy (PTCA).

        Description :

    Abciximab (c7E3) is a chimeric mouse-human monoclonal

    antibody directed against the GP IIb/IIIa receptor; its mechanism

    of action is thought to be steric hindrance of the receptor itself as   

    opposed to direct binding to the RGD binding site of the receptor.  

    It also inhibits the vitronectin (a_v b₃)receptor, which mediates

    both platelet coagulation as well as endothelial and vascular  

    smooth muscle cell proliferation.

    Dosage: 0.25 mg/kg administered 10-60 minutes before the   

    start of PTCA ` followed by a continuous I.V.. Injection of

    10 mcg/min. for 12 hours.
 

    Presentations:        Vial 5ml                
                                         MRP         Retailer       Stockiest

                                    19740.00    15792.00      14212.80